Zentalis Pharmaceuticals (ZNTL) Common Equity (2019 - 2026)

Zentalis Pharmaceuticals' Common Equity history runs 8 years deep, the most recent figure standing at $182.7 million for Q1 2026.

• On a quarterly basis, Common Equity fell 38.15% year-over-year to $182.7 million in Q1 2026; TTM through Mar 2026 was $182.7 million, a 38.15% decrease from a year earlier, with the FY2025 full-year figure at $216.2 million, down 35.88% from the prior year.
• Common Equity eased to $182.7 million in Q1 2026 per ZNTL's latest filing, from $216.2 million in the prior quarter.
• Across five years, Common Equity topped out at $523.3 million in Q2 2023 and bottomed at $182.7 million in Q1 2026.
• The 5-year median for Common Equity is $382.6 million (2024), against an average of $366.7 million.
• Across the five-year window, Common Equity surged 90.96% in 2022 and plunged 38.15% in 2026, its largest moves.
• Year by year, Common Equity stood at $434.0 million in 2022, then advanced by 0.78% to $437.4 million in 2023, then dropped by 22.91% to $337.2 million in 2024, then sank by 35.88% to $216.2 million in 2025, then slipped by 15.51% to $182.7 million in 2026.
• Per Business Quant, the three latest ZNTL Common Equity figures stand at $182.7 million (Q1 2026), $216.2 million (Q4 2025), and $252.9 million (Q3 2025).